Now that Asthma guidelines recommend ICS use to treat asthma flare-ups, are we to advise parents to deliver both albuterol AND ICS to school for use to treat flare up at school?

Hello,

In light of COVID-19 and young children with asthma in school, many of us will be deliveing albuterol and other inhaled medications to students via MDI and spacer, however there are students with special needs and those of young age who are not able to effectively take inhaled medications by MDI / spacer. What methods of delivering nebulizer treatments safely to these students have been explored or discussed?

Thank you,

Dan 

I would like to better understand about home assessment...if one is making a decision about triggers, can we assume ALL those patients have been allergy tested? 

What is the best way to get actual cost data, for example inpatient cost, medication costs, etc? Is there a national standard set of data available that can be used to calculate ROI? Otherwise, that data is hard to obtain in an individual setting.

I am not sure how the questions are being answered. First time user for me in this format.

What is the expanded reimbursement for providers?

During the process did you work with undocumented families?

What is the best way to get cost data, such as inptaient, medication costs, etc? Is the a standard set that is acceptable by various sources?

Does the Home Assessment include surveying the exposure to outdoor air (i.e. status of windows/doors).  Does the Home Assessment survey the outdoor exposures in close proximity (300 yards) to the home?  For example, what if crops are fertilized or crop dusted and are in close proximity to the home?  Folks are always talking about only 15% of time is spent outdoors.  However, patients carry in exposures into the home; whether pollen, VOC's, etc.